| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PCVX | Common Stock | Options Exercise | $16.6K | +3.1K | +99.2% | $5.35 | 6.23K | Nov 18, 2021 | Direct | F1 |
| transaction | PCVX | Common Stock | Sale | -$73.1K | -2.99K | -47.95% | $24.50 | 3.24K | Nov 18, 2021 | Direct | F1, F2, F3 |
| transaction | PCVX | Common Stock | Sale | -$2.9K | -115 | -3.55% | $25.20 | 3.13K | Nov 18, 2021 | Direct | F1, F2, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PCVX | Stock Option (right to buy) | Options Exercise | $0 | -3.1K | -0.59% | $0.00 | 522K | Nov 18, 2021 | Common Stock | 3.1K | $5.35 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | Includes shares acquired under the Vaxcyte, Inc. employee stock purchase plan on November 17, 2020 of 1,562 shares and May 17, 2021 of 1,563 shares. |
| F2 | The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| F3 | The price reported is a weighted-average price. The shares were sold at prices ranging from $24.04 to $24.86. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F4 | The price reported is a weighted-average price. The shares were sold at prices ranging from $25.08 to $25.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F5 | 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. |